Key result
Danaparoid can be used for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia, and a lower dose than recommended may minimize bleeding complications.
Why the study?
Does danaparoid provide safe and effective anticoagulation for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia?
Case Report (n=1)
Does danaparoid provide safe and effective anticoagulation for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia?
Danaparoid at a lower-than-recommended dose may provide effective anticoagulation while minimizing bleeding during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.
Danaparoid may support CPB anticoagulation in HIT at reduced doses; single case report leaves open need for prospective validation.
Anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia requires the use of other anticoagulants. We report a case in whom this was achieved using the heparinoid danaparoid (Orgaran). Based on our experience and a review of the literature, we provide guidelines for managing these rare patients. A danaparoid dose substantially lower than that recommended by the manufacturer may minimize bleeding complications.
No takes yet. Share an insight, caveat, or question.
Gillis et al. (1997) conducted a case report in Heparin-induced thrombocytopenia requiring cardiopulmonary bypass (n=1). Danaparoid (Orgaran) was evaluated. Danaparoid can be used for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia, and a lower dose than recommended may minimize bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: